These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
The stability is led by healthy demand in the domestic and emerging markets
The study will be published on the pre-print server, medRXiv, shortly
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Subscribe To Our Newsletter & Stay Updated
